Mereo BioPharma Enters Material Definitive Agreement
Ticker: MREO · Form: 8-K · Filed: Jun 14, 2024 · CIK: 1719714
| Field | Detail |
|---|---|
| Company | Mereo Biopharma Group PLC (MREO) |
| Form Type | 8-K |
| Filed Date | Jun 14, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $3.99, $3.75060, $45.9 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, definitive-agreement
TL;DR
Mereo BioPharma just signed a big deal, details TBD.
AI Summary
On June 14, 2024, Mereo BioPharma Group plc entered into a material definitive agreement. The filing does not provide specific details on the agreement, the counterparty, or any associated financial figures.
Why It Matters
This filing indicates a significant new contract or partnership for Mereo BioPharma, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and impact of the agreement.
Key Players & Entities
- Mereo BioPharma Group plc (company) — Registrant
FAQ
What is the nature of the material definitive agreement entered into by Mereo BioPharma Group plc?
The filing does not specify the nature of the agreement, only that one has been entered into on June 14, 2024.
Who is the counterparty to this material definitive agreement?
The filing does not disclose the name of the other party involved in the agreement.
Are there any financial terms or dollar amounts associated with this agreement mentioned in the filing?
No specific financial terms or dollar amounts related to the agreement are provided in this 8-K filing.
When was this material definitive agreement officially entered into?
The agreement was entered into on June 14, 2024.
What specific item numbers are being reported in this 8-K filing?
This 8-K filing reports on Item 1.01 (Entry into a Material Definitive Agreement), Item 9.01 (Financial Statements and Exhibits), and Item 5.01 (Regulation FD Disclosure).
Filing Stats: 953 words · 4 min read · ~3 pages · Grade level 12 · Accepted 2024-06-14 16:30:58
Key Financial Figures
- $3.99 — price of the Underwritten Securities is $3.99 per ADS, and the Underwriters have agre
- $3.75060 — he Underwriting Agreement at a price of $3.75060 per ADS. The Company expects to receive
- $45.9 m — eeds from the offering of approximately $45.9 million, after deducting underwriting dis
Filing Documents
- d828399d8k.htm (8-K) — 32KB
- d828399dex11.htm (EX-1.1) — 228KB
- d828399dex51.htm (EX-5.1) — 64KB
- d828399dex991.htm (EX-99.1) — 12KB
- g828399dsp001b.jpg (GRAPHIC) — 3KB
- g828399page001.jpg (GRAPHIC) — 3KB
- 0001193125-24-161662.txt ( ) — 594KB
- mreo-20240614.xsd (EX-101.SCH) — 3KB
- mreo-20240614_def.xml (EX-101.DEF) — 15KB
- mreo-20240614_lab.xml (EX-101.LAB) — 24KB
- mreo-20240614_pre.xml (EX-101.PRE) — 16KB
- d828399d8k_htm.xml (XML) — 6KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Exhibit 1.1 Underwriting Agreement, dated June 14, 2024, by and among the Company and Jefferies LLC, Leerink Partners LLC and Cantor Fitzgerald & Co. as underwriters. 5.1 Opinion of Latham & Watkins (London) LLP. 23.1 Consent of Latham & Watkins (London) LLP (contained in Exhibit 5.1). 99.1 Press Release, dated June 14, 2024 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: June 14, 2024 MEREO BIOPHARMA GROUP PLC By: /s/ Charles Sermon Name: Charles Sermon Title: General Counsel